Myriad Genetics, Inc [MYGN] stock is trading at $10.41, up 1.56%. An important factor to consider is whether the stock is rising or falling in short-term value. The MYGN shares have gain 0.68% over the last week, with a monthly amount drifted -16.39%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Myriad Genetics, Inc [NASDAQ: MYGN] stock has seen the most recent analyst activity on March 12, 2025, when Piper Sandler upgraded its rating to a Overweight and also boosted its price target to $12.50 from $11.50. Previously, Craig Hallum started tracking the stock with Buy rating on February 12, 2025, and set its price target to $29. On December 10, 2024, UBS initiated with a Neutral rating and assigned a price target of $18 on the stock. Leerink Partners downgraded its rating to a Market Perform and decreased its price target to $21 on December 09, 2024. Morgan Stanley initiated its recommendation with a Equal-Weight and recommended $32 as its price target on September 19, 2024. Wells Fargo started tracking with a Overweight rating for this stock on August 28, 2024, and assigned it a price target of $35. In a note dated June 27, 2024, Scotiabank initiated an Sector Outperform rating and provided a target price of $29 on this stock.
Myriad Genetics, Inc [MYGN] stock has fluctuated between $9.36 and $29.30 over the past year. Currently, Wall Street analysts expect the stock to reach $24.63 within the next 12 months. Myriad Genetics, Inc [NASDAQ: MYGN] shares were valued at $10.41 at the most recent close of the market. An investor can expect a potential return of 136.6% based on the average MYGN price forecast.
Analyzing the MYGN fundamentals
Myriad Genetics, Inc [NASDAQ:MYGN] reported sales of 837.60M for the trailing twelve months, which represents a growth of 7.12%. Gross Profit Margin for this corporation currently stands at 0.69% with Operating Profit Margin at -0.14%, Pretax Profit Margin comes in at -0.14%, and Net Profit Margin reading is -0.14%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is -0.15 and Total Capital is -0.12. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 10.03 points at the first support level, and at 9.66 for the second support level. However, for the 1st resistance point, the stock is sitting at 11.11, and for the 2nd resistance point, it is at 11.82.
Ratios To Look Out For
For context, Myriad Genetics, Inc’s Current Ratio is 1.82. On the other hand, the Quick Ratio is 1.65, and the Cash Ratio is 0.65. Considering the valuation of this stock, the price to sales ratio is 1.13, the price to book ratio is 1.36.
Transactions by insiders
Recent insider trading involved DIAZ PAUL J, President and CEO, that happened on Oct 11 ’24 when 15000.0 shares were sold. Officer, DIAZ PAUL J completed a deal on Oct 11 ’24 to buy 15000.0 shares. Meanwhile, Officer Ancona Margaret bought 11538.0 shares on Aug 21 ’24.
